77 related articles for article (PubMed ID: 16259048)
1. Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane.
Negrín MA; Vázquez-Polo FJ
Health Econ; 2006 Apr; 15(4):363-72. PubMed ID: 16259048
[TBL] [Abstract][Full Text] [Related]
2. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
Negrín MA; Vázquez-Polo FJ
J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
[TBL] [Abstract][Full Text] [Related]
3. Bayesian regression models for cost-effectiveness analysis.
Polo FJ; Negrín M; Badía X; Roset M
Eur J Health Econ; 2005 Mar; 6(1):45-52. PubMed ID: 15517461
[TBL] [Abstract][Full Text] [Related]
4. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
[TBL] [Abstract][Full Text] [Related]
6. Bayesian cost-effectiveness analysis from clinical trial data.
O'Hagan A; Stevens JW; Montmartin J
Stat Med; 2001 Mar; 20(5):733-53. PubMed ID: 11241573
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
[TBL] [Abstract][Full Text] [Related]
8. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
Bishai D; Colchero A; Durack DT
AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
[TBL] [Abstract][Full Text] [Related]
9. Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope.
Hoch JS; Rockx MA; Krahn AD
BMC Health Serv Res; 2006 Jun; 6():68. PubMed ID: 16756680
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
11. A Bayesian model averaging approach for cost-effectiveness analyses.
Conigliani C; Tancredi A
Health Econ; 2009 Jul; 18(7):807-21. PubMed ID: 18792078
[TBL] [Abstract][Full Text] [Related]
12. Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin.
Craig BA; Black MA
Expert Rev Pharmacoecon Outcomes Res; 2001 Oct; 1(1):37-46. PubMed ID: 19807506
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness as an outcome in randomized clinical trials.
Hlatky MA; Owens DK; Sanders GD
Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
15. Costs and effects in lumbar spinal fusion. A follow-up study in 136 consecutive patients with chronic low back pain.
Soegaard R; Christensen FB; Christiansen T; Bünger C
Eur Spine J; 2007 May; 16(5):657-68. PubMed ID: 16871387
[TBL] [Abstract][Full Text] [Related]
16. The impact of age on cost-effectiveness ratios and its control in decision making.
Baltussen R; Leidl R; Ament A
Health Econ; 1996; 5(3):227-39. PubMed ID: 8817297
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness with multiple outcomes.
Bjørner J; Keiding H
Health Econ; 2004 Dec; 13(12):1181-90. PubMed ID: 15386670
[TBL] [Abstract][Full Text] [Related]
18. Consequences of HIV prevention interventions and programs: spectrum, selection, and quality of outcome measures.
Holtgrave DR; Pinkerton SD
AIDS; 2000 Sep; 14 Suppl 2():S27-33. PubMed ID: 11061639
[TBL] [Abstract][Full Text] [Related]
19. Bayesian estimation of cost-effectiveness from censored data.
Heitjan DF; Kim CY; Li H
Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
[TBL] [Abstract][Full Text] [Related]
20. Bayesian estimation of cost-effectiveness: an importance-sampling approach.
Heitjan DF; Li H
Health Econ; 2004 Feb; 13(2):191-8. PubMed ID: 14737756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
